Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Virology

• Publication date

  2006-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.02094-05PMID 16699036PMCID PMC1472165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection

  2006cited by this paper
• Anti-V 3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian / Human Immunodeficiency Virus Infection

  2006cited by this paper
• Induction of Positive Cellular and Humoral Immune Responses by a Prime-Boost Vaccine Encoded with Simian Immunodeficiency Virus gag/pol1

  2006cited by this paper
• Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins

  2005cited by this paper
• Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

  2005cited by this paper
• Vaccination of Rhesus Macaques with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Env V3 Elicits Neutralizing Antibody-Mediated Protection against Simian-Human Immunodeficiency Virus with a Homologous but Not a Heterologous V3 Motif

  2005cited by this paper
• Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys

  2005cited by this paper
• Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles

  2005cited by this paper
• Comparative Immunogenicity of Human Immunodeficiency Virus Particles and Corresponding Polypeptides in a DNA Vaccine

  2005cited by this paper
• Medicinal chemistry: Best of both worlds?

  2005cited by this paper
• The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection

  2004cited by this paper
• Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope

  2004cited by this paper
• The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope

  2004cited by this paper
• A Consecutive Priming-Boosting Vaccination of Mice with Simian Immunodeficiency Virus (SIV) gag/pol DNA and Recombinant Vaccinia Virus Strain DIs Elicits Effective Anti-SIV Immunity

  2004cited by this paper
• The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12.

  2003cited by this paper
• HIV sequence compendium 2002

  2002cited by this paper
• Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

  2002cited by this paper
• Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization

  2002cited by this paper
• Challenges and opportunities for development of an AIDS vaccine

  2001cited by this paper
• Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope

  2001cited by this paper
• gp120: Biologic aspects of structural features.

  2001cited by this paper
• Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1

  2001cited by this paper
• Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.

  2001cited by this paper
• Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95‐up‐regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus

  2000cited by this paper
• A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey.

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes

  1998cited by this paper
• Capture of an early fusion-active conformation of HIV-1 gp41

  1998cited by this paper
• Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

  1997cited by this paper
• Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop

  1997cited by this paper
• Correlation of Titer of Antibody to Principal Neutralizing Domain of HIVMN Strain with Disease Progression in Japanese Hemophiliacs Seropositive for HIV Type 1

  1997cited by this paper
• A vaccine for HIV type 1: the antibody perspective.

  1997cited by this paper
• Host factors in the pathogenesis of HIV disease

  1997cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• The Instructive Role of Innate Immunity in the Acquired Immune Response

  1996cited by this paper
• CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

  1996cited by this paper
• CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

  1996cited by this paper
• Human studies in the development of human immunodeficiency virus vaccines.

  1995cited by this paper
• Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.

  1995cited by this paper
• Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120

  1995cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41

  1995cited by this paper
• Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

  1995cited by this paper
• Neutralization of HIV-1

  1994cited by this paper
• Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

  1994cited by this paper
• Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

  1994cited by this paper
• Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization

  1994cited by this paper
• Dilemma of Neutralization Resistance of HIV-1 Field Isolates and Vaccine Development

  1994cited by this paper
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

  1993cited by this paper
• Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

  1993influential reference
• Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

  1992cited by this paper
• Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.

  1992cited by this paper
• Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1992cited by this paper
• Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

  1992cited by this paper
• Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain

  1992cited by this paper
• Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain

  1992cited by this paper
• Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

  1992cited by this paper
• Characterization of a Mouse/Human Chimeric Monoclonal Antibody (Cβ1) to a Principal Neutralizing Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein

  1992cited by this paper
• Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

  1991cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system.

  1991cited by this paper
• Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding

  1991cited by this paper
• Characteristics of the Principal Neutralizing Determinant of HIV-1 Prevalent in Japan

  1991cited by this paper
• Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene

  1991cited by this paper
• HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide

  1990cited by this paper
• Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

  1990cited by this paper
• Generation of human monoclonal antibodies to human immunodeficiency virus.

  1989cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

  1988cited by this paper
• Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

  1985cited by this paper
• Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

  1984cited by this paper
• Continuous cultures of fused cells secreting antibody of predefined specificity

  1975cited by this paper

• CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors

  2026cites this paper
• Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors.

  2025cites this paper
• Peptides for Vaccine Development

  2022cites this paper
• Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.

  2022cites this paper
• Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

  2021cites this paper
• Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.

  2021cites this paper
• Sequential immunization induces strong and broad immunity against all four dengue virus serotypes

  2020cites this paper
• Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance

  2020cites this paper
• Prediction of contact residues in anti-HIV neutralizing antibody by deep learning.

  2020cites this paper
• Peptides to combat viral infectious diseases

  2020cites this paper
• Sequential immunization induces strong and broad immunity against all four dengue virus serotypes

  2020cites this paper
• Induction of cross‐neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines

  2020cites this paper
• Peptide-Based Vaccination for Antibody Responses Against HIV

  2019cites this paper
• Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication

  2019cites this paper
• Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.

  2019cites this paper
• Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

  2017cites this paper
• Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

  2017cites this paper
• Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes

  2017cites this paper
• Progress toward active or passive HIV-1 vaccination

  2017cites this paper
• Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk

  2017cites this paper
• Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization.

  2017cites this paper
• Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

  2016cites this paper
• Generation of a neutralization-resistant CCR5 tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6.

  2016cites this paper
• Small‐Molecule CD4 Mimics Containing Mono‐cyclohexyl Moieties as HIV Entry Inhibitors

  2016cites this paper
• Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.

  2016cites this paper
• A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.

  2016cites this paper
• Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.

  2015cites this paper
• Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus

  2015cites this paper
• Structural basis of clade‐specific HIV‐1 neutralization by humanized anti‐V3 monoclonal antibody KD‐247

  2015influential citation
• Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies

  2015cites this paper
• Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1

  2015cites this paper
• Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.

  2014influential citation
• The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

  2014cites this paper
• A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.

  2013cites this paper
• Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic.

  2013cites this paper
• Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium

  2013cites this paper
• Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

  2013cites this paper
• Antibody Guided Exploration of V3 Exposure on Subtype C HIV

  2012cites this paper
• Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.

  2012cites this paper
• Dynamic appearance of antigenic epitopes effective for viral neutralization during membrane fusion initiated by interactions between HIV-1 envelope proteins and CD4/CXCR4.

  2012cites this paper
• Candidate Antibody-Based Therapeutics Against HIV-1

  2012cites this paper
• Immunotherapeutic restoration in HIV-infected individuals.

  2011cites this paper
• Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope

  2011cites this paper
• Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

  2010cites this paper
• An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

  2010cites this paper
• Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF

  2010cites this paper
• Human immunodeficiency virus type 1 evasion of a neutralizing anti-V 3 antibody involves acquisition of a potential glycosylation site in V 2

  2010cites this paper
• Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants

  2010cites this paper
• Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.

  2010cites this paper
• Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue

  2009cites this paper
• Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization.

  2008cites this paper
• Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

  2007cites this paper
• Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate

  2007cites this paper
• Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

  2007cites this paper
• Anti-V 3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian / Human Immunodeficiency Virus Infection

  2006cites this paper
• Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection

  2006cites this paper
• Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors

  2006cites this paper
• Survey of the year 2003 commercial optical biosensor literature

  2005cites this paper